Opinion|Videos|October 11, 2024
Impact of IFM 2009 and DETERMINATION Studies
Key Takeaways
- Triplet therapy with VRd has improved progression-free survival in NDMM, altering induction treatment strategies.
- Clinicians now prioritize aggressive initial treatment to maximize PFS, influenced by VRd's efficacy.
Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The pivotal IFM 2009 study found that VRd (bortezomib, lenalidomide, and dexamethasone) followed by transplantation significantly improved progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM). How did the introduction of triplet therapy prior to transplant change the clinician mindset when deciding induction treatment, and how has that impacted studies that came after?
- (Dr Adams) In DETERMINATION, VRd with upfront transplant was associated with longer PFS. How did this trial change the goals of primary therapy for patients with NDMM?
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
4
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
5